切换至 "中华医学电子期刊资源库"

中华乳腺病杂志(电子版) ›› 2017, Vol. 11 ›› Issue (06) : 325 -330. doi: 10.3877/cma.j.issn.1674-0807.2017.06.002

论著

腋窝逆向淋巴结示踪术在乳腺癌患者选择性腋窝淋巴结清扫中的应用
王璐1, 许雪宁1, 朱妍慧1, 钱易1, 陈华1, 陆琦1, 潘红1, 夏添松1, 周文斌1, 陈琳1, 凌立君1, 刘晓安1,()   
  1. 1.210029 南京医科大学第一附属医院乳腺外科
  • 收稿日期:2016-11-10 出版日期:2017-12-01
  • 通信作者: 刘晓安
  • 基金资助:
    国家自然科学基金项目资助(81572602)

Clinical application of axillary reverse mapping in breast cancer patients undergoing axillary lymph node dissection

Lu Wang1, Xuening Xu1, Yanhui Zhu1, Yi Qian1, Hua. Chen1, Qi Lu1, Hong Pan1, Tiansong Xia1, Wenbin Zhou1, Lin Chen1, Lijun Ling1, Xiaoan Liu1,()   

  1. 1.Department of Breast Surgery, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
  • Received:2016-11-10 Published:2017-12-01
  • Corresponding author: Xiaoan Liu
引用本文:

王璐, 许雪宁, 朱妍慧, 钱易, 陈华, 陆琦, 潘红, 夏添松, 周文斌, 陈琳, 凌立君, 刘晓安. 腋窝逆向淋巴结示踪术在乳腺癌患者选择性腋窝淋巴结清扫中的应用[J/OL]. 中华乳腺病杂志(电子版), 2017, 11(06): 325-330.

Lu Wang, Xuening Xu, Yanhui Zhu, Yi Qian, Hua. Chen, Qi Lu, Hong Pan, Tiansong Xia, Wenbin Zhou, Lin Chen, Lijun Ling, Xiaoan Liu. Clinical application of axillary reverse mapping in breast cancer patients undergoing axillary lymph node dissection[J/OL]. Chinese Journal of Breast Disease(Electronic Edition), 2017, 11(06): 325-330.

目的

探讨乳腺癌患者行选择性腋窝淋巴结清扫术时,通过施行腋窝逆向淋巴结示踪术(ARM)来保留引流上肢淋巴液的淋巴结的可行性。

方法

根据纳入、排除标准,选取南京医科大学第一附属医院乳腺外科2015 年4—7 月拟行腋窝淋巴结清扫术的80 例女性乳腺癌患者进行前瞻性研究。用纳米炭混悬液行ARM,以胸背血管和腋静脉为界,将腋窝淋巴结分为3 区:腋静脉上方区、胸背血管外侧区、胸背血管内侧区。 通过病理分析淋巴结有无转移。

结果

80 例患者中,72 例(90%)患者可显示黑染淋巴结,40 例患者有腋窝淋巴结转移。 在40 例腋窝淋巴结转移患者中,纳米炭混悬液注射距手术开始时间<6 h 的N1 和N2 期患者共14 例,腋静脉上方淋巴结转移率为0/8,胸背血管外侧淋巴结转移率为0/11,胸背血管内侧转移率为5/11;而注射时间≥6 h 的N1、N2 期患者共15 例,腋静脉上方淋巴结转移率为0/6,胸背血管外侧淋巴结转移率为3/11,胸背血管内侧转移率为7/11。 在胸背血管外侧和腋静脉上方,引流上肢淋巴液的淋巴结转移率很低。

结论

N1、N2 期乳腺癌患者术前6 h 内用纳米炭混悬液行ARM,胸背血管外侧和腋静脉上方淋巴结予以保留的价值可能较大。

Objective

To explore the feasibility of axillary reverse mapping (ARM) in axillary lymph node dissection (ALND) for breast cancer patients in order to preserve the lymph nodes with lymphatic drainage in upper extremities.

Methods

A total of 80 breast cancer patients who were to receive ALND in the First Affiliated Hospital of Nanjing Medical University from April 2015 to July 2015 were enrolled in this perspective study according to the inclusion and exclusion criteria. Carbon nanoparticle suspension was used for ARM procedure. Axillary lymph nodes were categorized to three regions based on their locations to the axillary vein and thoracodorsal vessel: the region above axillary vein, the lateral region of thoracodorsal vessel and the medial region of thoracodorsal vessel. All the lymph nodes were dissected and pathologically detected whether lymph node metastasis existed.

Results

Black dyed lymph nodes were identified in 72 out of 80 patients(90%) and axillary lymph node metastasis was observed in 40 patients. In 40 patients with axillary lymph node metastasis,14 in N1-2 stage patients had an interval between tracer injection and surgery<6 h; among them, the lymph node metastasis rate was 0/8 in the region above axillary vein, 0/11 in the lateral region of thoracodorsal vessel and 5/11 in the medial region of thoracodorsal vessel. There were 15 patients in N1-2 stage with an interval between tracer injection and surgery ≥6 h; among them, the lymph node metastasis rate was 0/6 in the region above axillary vein,3/11 in the lateral region of thoracodorsal vessel and 7/11 in the medial region of thoracodorsal vessel. In the region lateral to thoracodorsal vessel and above axillary vein, the metastasis rate of lymph nodes with lymphatic drainage in the upper extremities was low.

Conclusion

If ARM using carbon nanoparticle suspension is performed within 6 h before axillary lymph node dissection in N1-2 stage breast cancer patients, lymph nodes in the region lateral to thoracodorsal vessel and above axillary vein may be preserved.

图1 乳腺癌患者术前注射纳米炭混悬液
表1 80 例乳腺癌患者临床病理特征
表2 80 例乳腺癌患者的病理N 分期及淋巴结纳米炭黑染情况(例)
图2 乳腺癌患者行腋窝逆向淋巴结示踪术 注:a 图中箭头所示腋静脉上方黑染淋巴结; b 图中箭头所示胸背血管周围黑染淋巴结; c 图所示,打钉处为标记的胸背血管位置,箭头所示胸背血管周围黑染淋巴结
表3 40 例腋窝淋巴结转移乳腺癌患者腋窝黑染淋巴结转移分布情况
表4 21 例纳米炭染色时间<6 h 的乳腺癌患者腋窝黑染淋巴结转移分布情况
表5 19 例纳米炭染色时间≥6 h 的乳腺癌患者腋窝黑染淋巴结转移分布情况
表6 40 例腋窝淋巴结转移乳腺癌患者腋窝未黑染淋巴结转移分布情况
[1]
Leidenius M, Leivonen M,Vironen J,et al. The consequences of longtime arm morbidity in node-negative breast cancer patients with sentinel node biopsy or axillary clearance [J]. J Surg Oncol, 2005,92(1):23-31.
[2]
Mansel RE, Fallowfield L, Kissin M, et al. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC trial [J]. J Natl Cancer Inst,2006,98(9):599-609.
[3]
Rönkä R, von Smitten K, Tasmuth T, et al. One-year morbidity after sentinel node biopsy and breast surgery [J]. Breast,2005,14(1):28-36.
[4]
Pavlista D, Eliska O. Analysis of direct oil contrast lymphography of upper limb lymphatics traversing the axilla—a lesson from the past—contribution to the concept of axillary reverse mapping [J]. Eur J Surg Oncol,2012,38(5):390-394.
[5]
Sakorafas GH, Peros G, Cataliotti L, et al. Lymphedema following axillary lymph node dissection for breast cancer [J]. Surg Oncol,2006,15(3):153-165.
[6]
Tausch C, Baege A, Dietrich D, et al. Can axillary reverse mapping avoid lymphedema in node positive breast cancer patients? [J]. Eur J Surg Oncol,2013,39(8):880-886.
[7]
Ikeda K, Ogawa Y, Kajino C, et al. The influence of axillary reverse mapping related factors on lymphedema in breast cancer patients [J].Eur J Surg Oncol,2014,40(7):818-823.
[8]
Noguchi M, Miura S, Morioka E, et al. Is axillary reverse mapping feasible in breast cancer patients? [J]. Eur J Surg Oncol,2015,41(4):442-449.
[9]
Ngui NK, French J, Kilby CJ, et al. Axillary reverse mapping in patients with breast cancer: Is it oncologically safe? [J]. J Surg Oncol,2016,113(7):726-731.
[10]
National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: breast cancer screening and diagnosis,version. 1. 2010, 11/03/03 2009 [ M ]. Washington: National Comprehensive Cancer Network,Inc,2009:3.
[11]
Bedrosian I, Babiera GV, Mittendorf EA, et al. A phase I study to assess the feasibility and oncologic safety of axillary reverse mapping in breast cancer patients [J]. Cancer,2010,116(11):2543-2548.
[12]
Rubio IT, Cebrecos I, Peg V, et al. Extensive nodal involvement increases the positivity of blue nodes in the axillary reverse mapping procedure in patients with breast cancer[J]. J Surg Oncol,2012,106(1):89-93.
[13]
Ponzone R, Cont NT, Maggiorotto F, et al. Extensive nodal disease may impair axillary reverse mapping in patients with breast cancer [J].J Clin Oncol,2009,27(33):5547-5551.
[14]
Gobardhan PD, Wijsman JH, van Dalen T, et al. ARM: axillary reverse mapping the need for selection of patients [J]. Eur J Surg Oncol,2012,38(8):657-661.
[15]
Khandelwal R, Poovamma CU, Shilpy C, et al. Axillary reverse mapping: is it feasible in locally advanced breast cancer patients? [J].Breast Dis,2014,34(4):151-155.
[16]
Schunemann E Jr, Doria MT, Silvestre JB, et al. Prospective study evaluating oncological safety of axillary reverse mapping [J]. Ann Surg Oncol,2014,21(7):2197-2202.
[17]
刘坚,李佳璐,周俊,等.荧光法腋窝反向制图技术在乳腺癌手术中的可行性[J/CD]. 中华乳腺病杂志(电子版),2016,10(6):333-339.
[18]
Pavlista D, Eliska O. Relationship between the lymphatic drainage of the breast and the upper extremity: a postmortem study [J]. Ann Surg Oncol,2012,19(11):3410-3415.
[1] 王佳佳, 詹韵韵, 姜凡, 孙碧云, 毕玉, 李如冰, 彭梅. Peyton四步教学法在超声住院医师规范化培训颈部淋巴结分区中的应用[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 814-818.
[2] 李洋, 蔡金玉, 党晓智, 常婉英, 巨艳, 高毅, 宋宏萍. 基于深度学习的乳腺超声应变弹性图像生成模型的应用研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(06): 563-570.
[3] 河北省抗癌协会乳腺癌专业委员会护理协作组. 乳腺癌中心静脉通路护理管理专家共识[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 321-329.
[4] 刘晨鹭, 刘洁, 张帆, 严彩英, 陈倩, 陈双庆. 增强MRI 影像组学特征生境分析在预测乳腺癌HER-2 表达状态中的应用[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 339-345.
[5] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[6] 李乐平, 张荣华, 商亮. 腹腔镜食管胃结合部腺癌根治淋巴结清扫策略[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 9-12.
[7] 吴晖, 佴永军, 施雪松, 魏晓为. 两种解剖入路下行直肠癌侧方淋巴结清扫的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 40-43.
[8] 周世振, 朱兴亚, 袁庆港, 刘理想, 王凯, 缪骥, 丁超, 汪灏, 管文贤. 吲哚菁绿荧光成像技术在腹腔镜直肠癌侧方淋巴结清扫中的应用效果分析[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 44-47.
[9] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[10] 韩萌萌, 冯雪园, 马宁. 乳腺癌改良根治术后桡神经损伤1例[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 117-118.
[11] 庄宝雄, 邓海军. 单孔+1腹腔镜直肠癌侧方淋巴结清扫术[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 601-601.
[12] 贺斌, 马晋峰. 胃癌脾门淋巴结转移危险因素[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 694-699.
[13] 林逸, 钟文龙, 李锴文, 何旺, 林天歆. 广东省医学会泌尿外科疑难病例多学科会诊(第15期)——转移性膀胱癌的综合治疗[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 648-652.
[14] 陆镜明, 韩大为, 任耀星, 黄天笑, 向俊西, 张谞丰, 吕毅, 王傅民. 基于术前影像组学的肝内胆管细胞癌淋巴结转移预测的系统性分析[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 852-858.
[15] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
阅读次数
全文


摘要